Literature DB >> 20036025

Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.

Stefan Heringlake1, Michael Hofdmann, Anette Fiebeler, Michael P Manns, Wolff Schmiegel, Andrea Tannapfel.   

Abstract

BACKGROUND & AIMS: The aim of our study was to search for highly up-regulated genes in primary malignant liver tumours and to analyse their expression at the mRNA- and protein level.
METHODS: Using a random-based gene fishing approach (representational difference analysis coupled to array hybridisation) we identified 7 genes high abundantly expressed in hepatocellular carcinoma (HCC) as compared to non-neoplastic liver tissue, among them a gene fragment of the aldo-ketoreductase (AKR) superfamily. Full length cloning and sequencing of the gene fragment identified it as B10 gene of the AKR-family 1 (AKR1B10). For expression analysis on transcriptional level quantitative real-time RT-PCR was performed in 22 HCC and 22 non-neoplastic liver cirrhotic tissues.
RESULTS: Our data demonstrate significantly higher expression levels of AKR1B10-mRNA in HCC compared to non-tumourous cirrhotic liver tissue (p<0.0001). To evaluate its protein expression in primary malignant liver tumours, we investigated tissue arrays of 210 HCC and 51 cholangiocarcinomas (CC) by immunohistochemistry, using a monoclonal antibody against AKR1B10. Protein staining of AKR1B10 was significantly increased in well and moderately differentiated tumours compared to corresponding non-neoplastic liver tissue (p=0.023). However, AKR1B10-staining decreased in advanced, low differentiated tumours with a significant inverse correlation between AKR1B10-staining and tumour proliferation, indicated by Ki67 (MIB-1) staining (r=-0.89, p=0.02).
CONCLUSION: The over-expression of AKR1B10 in early stages of well and moderately differentiated tumours and its down-regulation in advanced tumour-stages with low grade of differentiation demonstrated that AKR1B10 may be a helpful marker for differentiation and proliferation of HCC and CC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036025     DOI: 10.1016/j.jhep.2009.11.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

1.  Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.

Authors:  Kristina A Matkowskyj; Han Bai; Jie Liao; Wanying Zhang; Haonan Li; Sambasiva Rao; Reed Omary; Guang-Yu Yang
Journal:  Hum Pathol       Date:  2013-12-18       Impact factor: 3.466

2.  Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.

Authors:  Fuminori Sonohara; Yoshikuni Inokawa; Mitsuhiro Hishida; Mitsuro Kanda; Yoko Nishikawa; Suguru Yamada; Tsutomu Fujii; Hiroyuki Sugimoto; Yasuhiro Kodera; Shuji Nomoto
Journal:  Oncol Lett       Date:  2016-10-11       Impact factor: 2.967

3.  Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.

Authors:  Yongzhen Liu; Jing Zhang; Hui Liu; Guiwen Guan; Ting Zhang; Leijie Wang; Xuewei Qi; Huiling Zheng; Chia-Chen Chen; Jia Liu; Deliang Cao; Fengmin Lu; Xiangmei Chen
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

4.  Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.

Authors:  Yasuhiro Hashimoto; Kengo Imanishi; Noriko Tokui; Teppei Okamoto; Akiko Okamoto; Shingo Hatakeyama; Takahiro Yoneyama; Takuya Koie; Noritaka Kamimura; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2011-12-27       Impact factor: 3.402

5.  Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.

Authors:  Tianxing Dai; Linsen Ye; Haoyuan Yu; Kun Li; Jing Li; Rongqiang Liu; Xu Lu; Mingbin Deng; Rong Li; Wei Liu; Yang Yang; Guoying Wang
Journal:  J Hepatocell Carcinoma       Date:  2021-08-30

6.  Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.

Authors:  Masataka Kanno; Kazunori Kawaguchi; Masao Honda; Rika Horii; Hajime Takatori; Tetsuro Shimakami; Kazuya Kitamura; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2019-02-01       Impact factor: 7.527

7.  Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).

Authors:  Haonan Li; Allison L Yang; Yeon Tae Chung; Wanying Zhang; Jie Liao; Guang-Yu Yang
Journal:  Carcinogenesis       Date:  2013-05-20       Impact factor: 4.944

8.  Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.

Authors:  Wanying Zhang; Haonan Li; Yihe Yang; Jie Liao; Guang-Yu Yang
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

9.  Aldo-Keto Reductases 1B in Endocrinology and Metabolism.

Authors:  Emilie Pastel; Jean-Christophe Pointud; Fanny Volat; Antoine Martinez; Anne-Marie Lefrançois-Martinez
Journal:  Front Pharmacol       Date:  2012-08-02       Impact factor: 5.810

10.  Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.

Authors:  Shunsuke Sato; Takuya Genda; Katsuharu Hirano; Hironori Tsuzura; Yutaka Narita; Yoshio Kanemitsu; Tetsu Kikuchi; Katsuyori Iijima; Ryo Wada; Takafumi Ichida
Journal:  Liver Int       Date:  2012-06-11       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.